Ingenium and Oxagen to Collaborate on Drug Targets

A collaboration involving genes relating to metabolic diseases located by target identification technology has been announced by Ingenium Pharmaceuticals AG (Munich, Germany) and Oxagen Limited (Abingdon, UK).

Under the agreement, Ingenium will use its Ingenotyping technology platform to develop animal models with defined gene alterations. Ingenotyping can provide in as little as four months a series of mammalian models that carry unique genetic alterations in any target gene of interest. These models include knockouts as well as more subtle functional alterations, such as increased or decreased gene target activity. The ingenotyping technology is based on a genetically subtle chemical process that generates point mutations in genes.

Oxagen is a biopharmaceutical company building a drug pipeline on targets validated in man through its genetics platform. The company specializes in target identification and validation in inflammatory and metabolic diseases and is creating a pipeline of drug targets for licensing to partner companies and for in-house development.

"Ingenotyping is extremely well-suited for accelerating the development of drug targets that are based on genetic findings because it allows researchers to work with models representing multiple types of functional gene alterations at an unprecedented high speed,” said Michael Nehls, M.D., Ph.D., chief executive and chief scientific officer at Ingenium.




Related Links:
Ingenium Pharma
Oxagen